Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation.

Laboratory tools to monitor infection burden are important to evaluate progress and determine endpoints in programs to eliminate lymphatic filariasis. We evaluated changes in Wuchereria bancrofti microfilaria, filarial antigen and Bm14 antibody in individuals who participated in a five-year mass drug administration trial in Papua New Guinea. Comparing values before treatment and one year after four annual treatments, the proportion of microfilaria positive individuals declined to the greatest degree, with less marked change in antibody and antigen rates. Considering children as sentinel groups who reflect recent transmission intensity, children surveyed before the trial were more frequently microfilaria and antibody positive than those examined one year after the trial stopped. In contrast, antigen positive rates were similar in the two groups. All infection indicators continued to decline five years after cessation of mass drug administration; Bm14 antibody persisted in the greatest proportion of individuals. These data suggest that Bm14 antibody may be a sensitive test to monitor continuing transmission during and after mass drug administration aimed at eliminating transmission of lymphatic filariasis.

[1]  E. Ottesen.  Global programme to eliminate lymphatic filariasis. , 2009, Releve epidemiologique hebdomadaire.

[2]  Gary J Weil,et al.  Diagnostic tools for filariasis elimination programs. , 2007, Trends in parasitology.

[3]  M. Alpers,et al.  Efficacy of single-dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea. , 2007, The American journal of tropical medicine and hygiene.

[4]  J. Kazura,et al.  Mathematical models and lymphatic filariasis control: monitoring and evaluating interventions. , 2006, Trends in parasitology.

[5]  G. Weil,et al.  Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[6]  W. Shannon,et al.  Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment , 2006, The Lancet.

[7]  Eric A Ottesen,et al.  Lymphatic filariasis: Treatment, control and elimination. , 2006, Advances in parasitology.

[8]  J. Kazura,et al.  Mass chemotherapy options to control lymphatic filariasis: a systematic review. , 2005, The Lancet. Infectious diseases.

[9]  G. Weil,et al.  Recombinant antigen-based antibody assays for the diagnosis and surveillance of lymphatic filariasis – a multicenter trial , 2004, Filaria journal.

[10]  J. Kazura,et al.  Lymphatic filariasis in Papua New Guinea: prospects for elimination , 2003, Medical Microbiology and Immunology.

[11]  M. Alpers,et al.  Mass treatment to eliminate filariasis in Papua New Guinea. , 2002, The New England journal of medicine.

[12]  D. Molyneux,et al.  Lymphatic filariasis elimination: progress in global programme development. , 2002, Annals of tropical medicine and parasitology.

[13]  D. Boakye,et al.  Development and standardization of a rapid, PCR-based method for the detection of Wuchereria bancrofti in mosquitoes, for xenomonitoring the human prevalence of bancroftian filariasis. , 2002, Annals of tropical medicine and parasitology.

[14]  R. Ramzy.  Field application of PCR-based assays for monitoring Wuchereria bancrofti infection in Africa. , 2002, Annals of tropical medicine and parasitology.

[15]  M. Alpers,et al.  Ecologic and biologic determinants of filarial antigenemia in bancroftian filariasis in Papua New Guinea. , 2001, The Journal of infectious diseases.

[16]  M. Alpers,et al.  Migration and dispersal of lymphatic filariasis in Papua New Guinea. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[17]  G. Weil,et al.  The ICT Filariasis Test: A rapid-format antigen test for diagnosis of bancroftian filariasis. , 1997, Parasitology today.

[18]  L. Nicolas,et al.  Reduction of Wuchereria bancrofti adult worm circulating antigen after annual treatments of diethylcarbamazine combined with ivermectin in French Polynesia. , 1997, The Journal of infectious diseases.

[19]  G. Weil,et al.  Parasite antigenemia without microfilaremia in bancroftian filariasis. , 1996, The American journal of tropical medicine and hygiene.

[20]  K. Curtis,et al.  Molecular characterization of a Brugia malayi intermediate filament protein which is an excretory-secretory product of adult worms. , 1995, Molecular and biochemical parasitology.

[21]  R. Speare,et al.  A comparison of the Og4C3 antigen capture ELISA, the Knott test, an IgG4 assay and clinical signs, in the diagnosis of Bancroftian filariasis. , 1993, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.

[22]  S. More,et al.  A highly specific and sensitive monoclonal antibody-based ELISA for the detection of circulating antigen in bancroftian filariasis. , 1990, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.